logo
Health Rounds: Semaglutide pill Rybelsus matches heart benefits of injectable versions

Health Rounds: Semaglutide pill Rybelsus matches heart benefits of injectable versions

Reuters02-04-2025
April 2 (Reuters) - (To receive the full newsletter in your inbox for free sign up here)
Novo Nordisk's (NOVOb.CO), opens new tab diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular benefits as the injectable forms of the drug, researchers reported at the American College of Cardiology scientific meeting in Chicago.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
In a trial of 9,650 patients with type 2 diabetes, who had clogged heart arteries and/or chronic kidney disease, those taking Rybelsus were overall 14% less likely to experience heart-related death, heart attack or stroke than those who received a placebo after an average follow-up of four years.
The researchers saw a 26% reduction in non-fatal heart attacks with oral semaglutide and a 12% reduction in non-fatal strokes, both of which 'are among the most common and devastating complications of diabetes,' study coauthor Dr. John Buse of the University of North Carolina School of Medicine said in a statement.
There was also a 7% lower rate of cardiovascular death with Rybelsus.
This level of risk reduction is in line with results from eight previous trials involving injectable GLP-1s, such as Novo's Ozempic and Eli Lilly's (LLY.N), opens new tab Trulicity, said study leader Dr. Darren McGuire of UT Southwestern Medical Center and Parkland Health in Dallas.
'The same cardiovascular benefits can be derived from the tablet that we've seen from the injectables before,' McGuire said in a statement.
Although the exact mechanism through which the drugs reduce cardiovascular risk is not known, their anti-inflammatory activity is thought to play a role.
The most common side effects reported in the study that was also published in The New England Journal of Medicine, opens new tab were gastrointestinal problems such as nausea, diarrhea, constipation and gas, which are also the most common side effects of injectable semaglutide.
'Semaglutide has been a mainstay of our efforts to reduce heart attack and stroke in people with diabetes,' Buse said. 'Having an oral option to deliver this highly effective therapy is a big advance.'
HEART FAILURE PATIENTS CAN STOP LIMITING FLUIDS
Heart failure patients do not benefit from restricted fluid intake, according to findings that may contradict current practice.
U.S. and European medical guidelines have long advised heart failure patients to limit their daily fluid intake to about six cups (1,500 milliliters), to help reduce fluid buildup in the lungs and extremities, but without much evidence to support this practice, researchers said at the ACC meeting.
In the trial of 504 patients with mild to moderate heart failure, there was no difference in health status after three months between individuals with unrestricted fluid intake compared with patients assigned to fluid restriction.
Nor were there any differences in safety outcomes, such as swelling or shortness of breath due to congestion from fluid overload in the body that occurs when the heart is too stiff or too weak to effectively pump blood, according to a report of the study published in Nature Medicine, opens new tab.
Patients in the fluid restriction group reported more problems with thirst, however.
There was a trend toward better health at three months among those with unrestricted fluid intake, but the difference between groups was not statistically significant and so could be due to chance.
'Our conclusion is that in patients with stable heart failure there is no need for fluid restriction,' study leader Dr. Roland van Kimmenade of Radboud University Medical Center in Nijmegen, Netherlands said in a statement.
MINIMALLY INVASIVE HEART PROCEDURES IMPROVING IN LOW-RISK PATIENTS
Physically fit patients who need heart procedures are traditionally referred for major surgery, but the benefits of minimally invasive procedures are starting to outweigh the disadvantages in these individuals, researchers reported at the ACC meeting.
In a trial called FAME 3, 1,500 relatively healthy patients with blockages in three coronary arteries, but not in the left main artery known as the 'widow maker', were recruited between 2014 and 2019.
They underwent either a percutaneous coronary intervention via a small incision through the skin, or coronary artery bypass grafting (CABG) surgery, which involves sawing through the breastbone and stopping the heart and requires weeks or months of recovery.
None of the patients was at particularly high risk for complications from open-heart surgery.
Researchers had earlier reported that one year into the study, the combined rate of death, stroke, heart attack, or need for a repeat procedure to reopen the arteries was higher in the minimally invasive group, suggesting the major surgery was still the best option for these patients.
But now, five years out, there is no significant difference in the composite of death, stroke, or heart attack between the two groups, the researchers say.
'This is the only study to compare CABG and PCI as they are currently used in cardiology – incorporating recent advances in surgical and minimally invasive techniques as well as in medical therapy – in patients with triple-vessel disease,' study leader Dr. William Fearon of Stanford University School of Medicine in California said in a statement.
Looking at the endpoints individually, rates of death and stroke were similar in the two groups, but PCI patients had higher risks for heart attack (8% vs 5%) and repeat revascularization (16% vs 8%) than the CABG group.
The narrowing of the outcomes difference between the two approaches is likely due to improved stent technology, the routine use of new techniques for selecting which arteries to treat with PCI, and greater patient adherence to medical therapy, Fearon's team said in The Lancet, opens new tab.
In a separate trial involving 1,478 relatively healthy patients who needed aortic valve replacement, rates of death or disabling stroke at five years were similar whether the valve was replaced through a small incision in the arm or via standard open-heart surgery, Dr. Michael Reardon of Houston Methodist Hospital and colleagues reported at the meeting and in the Journal of the American College of Cardiology, opens new tab.
However, in a third study of 1,618 patients who were at intermediate or high risk for surgical complications – also reported at the meeting and in the Journal of the American College of Cardiology, opens new tab - five-year outcomes were significantly better after minimally invasive procedures than after surgery, Reardon's team said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The 7 foods that could protect you from common fat jab side effect, suggest scientists
The 7 foods that could protect you from common fat jab side effect, suggest scientists

Scottish Sun

time5 hours ago

  • Scottish Sun

The 7 foods that could protect you from common fat jab side effect, suggest scientists

Find out more about side effects linked to fat jabs below NO WEIGH The 7 foods that could protect you from common fat jab side effect, suggest scientists Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WOMEN and older adults who use increasingly popular weight-loss drug semaglutide could protect themselves from a common side effect by eating more protein, say scientists. It may be an important step in reducing insulin resistance and preventing frailty in people with obesity, they add. Sign up for Scottish Sun newsletter Sign up 1 Women and older adults using semaglutide nay be at risk of losing muscle mass, previous studies have found Credit: Getty A previous study presented at ENDO 2025 suggested women and older adults using semaglutide, a GLP-1 receptor agonist, for weight loss may be at a higher risk of losing muscle mass. Muscle loss, also referred to as lean mass loss, is a frequent consequence of weight reduction in people with obesity. According to lead researcher Dr Melanie Haines of Massachusetts General Hospital and Harvard Medical School in a new study, this type of muscle loss can negatively influence metabolism and bone health. That's because muscle helps manage blood sugar levels after eating and contributes to bone strength. According to a study published in Diabetes, Obesity and Metabolism, up to 40 per cent of the total weight lost while using semaglutide may be lean mass. But Dr Haines noted it's still unclear which patients are most likely to lose muscle and how this muscle loss might impact blood sugar control. To explore this further, researchers observed 40 adults with obesity over a three-month period. Of these participants, 23 were treated with semaglutide, while the remaining 17 took part in a weight-loss programme called Healthy Habits for Life (HHL), which focuses on diet and lifestyle changes. The team then monitored shifts in the participants' muscle mass over the course of the study. They found participants who were prescribed semaglutide lost more weight than those who participated in the diet and lifestyle programme. Weight Loss Jabs - Pros vs Cons But the percent of weight loss that was lean mass was similar between the two groups. After accounting for weight loss, the researchers found in the semaglutide group, being older, female, or eating less protein was linked to greater muscle loss. Losing more muscle was also linked to less improvement in blood sugar levels. 'Older adults and women may be more likely to lose muscle on semaglutide, but eating more protein may help protect against this,' Haines said. 'Losing too much muscle may reduce the benefits of semaglutide on blood sugar control. "This means preserving muscle during weight loss with semaglutide may be important to reduce insulin resistance and prevent frailty in people with obesity.' There are both animal and plant-based sources of protein. Here are seven to include in your diet: Animal sources Lean meats - chicken breast, turkey, beef, and pork are excellent sources of high-quality protein, offering a range of vitamins and minerals. Fish - salmon, tuna, and other fish are rich in protein and omega-3 fatty acids. Eggs - a complete protein source, meaning it contains all nine essential amino acids. Dairy - milk, yogurt (especially Greek yogurt), and cheese (especially cottage cheese) are good sources of protein and calcium. Plant-based sources Legumes - beans, lentils, and peas are excellent sources of protein, fibre, and other nutrients. Nuts and seeds - almonds, walnuts, chia seeds, and pumpkin seeds offer protein, healthy fats, and vitamins. Tofu and soy products - tofu, tempeh, and edamame are good sources of protein, particularly for vegetarians and vegans. In the UK, semaglutide for weight loss is available under the brand name Wegovy, and is prescribed through specialist weight management services within the NHS. It's an injectable medication (once weekly) that is used alongside a reduced-calorie diet and increased physical activity. Ozempic, another semaglutide medication, is specifically for type 2 diabetes and is available on the NHS.

Centene posts surprise loss as medical costs surge, shares slump
Centene posts surprise loss as medical costs surge, shares slump

Reuters

time6 hours ago

  • Reuters

Centene posts surprise loss as medical costs surge, shares slump

July 25 (Reuters) - Centene (CNC.N), opens new tab on Friday posted a surprise quarterly loss, in yet another disappointment for investors in the sector that has suffered a series of setbacks due to rising costs in government-backed insurance plans. Shares of the company tumbled 14.5% in premarket trading, dragging down peers Elevance (ELV.N), opens new tab and Molina Healthcare (MOH.N), opens new tab, which have also warned of elevated costs in government-backed insurance plans. The insurance sector has been under strain for the past two years due to rising medical costs. On one hand, insurers are grappling with increased utilization of behavioral health services, home care, and high-cost drugs, while on the other, the expiration of pandemic-era subsidies and Medicaid protections has shifted enrollment toward sicker members, squeezing their margins. Centene, which largely focuses on government-sponsored plans, posted a medical cost ratio (MCR) of 93% for the quarter, well above Wall Street's expectation of 89.3% and a clear sign of pressure across all business lines. "The medical cost ratio for the quarter was surprisingly high and appeared related to all major lines of business, although its individual exchange business was likely the biggest culprit," said Morningstar analyst Julie Utterback. The quarterly loss was largely attributed to a downward revision in expected 2025 risk adjustment revenue, part of the Affordable Care Act's mechanism to balance costs across insurers. The adjustment, combined with rising Medicaid expenditure drove Centene to a second-quarter adjusted loss of $0.16 per share, versus an expected profit of $0.86, according to data compiled by LSEG. "We are disappointed by our second-quarter results, but we have a clear understanding of trends that have impacted performance, and are working with urgency and focus to restore our earnings trajectory," CEO Sarah London said. Centene said it would provide 2025 earnings expectations on the conference call. The company is in the process of requesting premium increases for Obamacare plans for 2026 to reflect a higher proportion of sicker patients who need more medical care, than it previously expected. Centene expects to be able to take corrective pricing actions for 2026 in states that represent a substantial majority of its membership in those plans.

HCA raises annual profit forecast on resilient demand for medical care
HCA raises annual profit forecast on resilient demand for medical care

Reuters

time7 hours ago

  • Reuters

HCA raises annual profit forecast on resilient demand for medical care

July 25 (Reuters) - HCA Healthcare (HCA.N), opens new tab raised its 2025 profit forecast on Friday as it expects sustained demand for medical procedures to cushion a hit from U.S. President Donald Trump's potential tariffs. Health insurers have flagged higher-than-anticipated costs in its individual plans that come under the Affordable Care Act, also known as Obamacare, and its Medicaid plans for low-income people. Analysts have said they expect this trend to benefit hospital operators, but warned that proposed federal budget cuts could hit their earnings. HCA earned second-quarter adjusted profit of $6.84 per share, beating analysts' estimates of $6.25 per share, according to data compiled by LSEG. The company expects 2025 profit to be about $25.50 to $27 per share, compared with its previous forecast of $24.05 to $25.85 per share.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store